Heterocyclic Analogues of Squamocin as Inhibitors of Mitochondrial Complex I. On the Role of the Terminal Lactone of Annonaceous Acetogenins

• Published in: Biochemistry (Easton) 2006-02, Vol.45 (8), p.2721-2728
• Main Authors: Duval, Romain A, Lewin, Guy, Peris, Eva, Chahboune, Nadia, Garofano, Aurelio, Dröse, Stefan, Cortes, Diego, Brandt, Ulrich, Hocquemiller, Reynald
• Format: Article
• Language: English
• Subjects: Acetogenins; Annona - enzymology; Annona - metabolism; Electron Transport Complex I - antagonists & inhibitors; Electron Transport Complex I - metabolism; Enzyme Inhibitors - chemical synthesis; Enzyme Inhibitors - pharmacology; Esters - chemistry; Fatty Alcohols - chemistry; Fatty Alcohols - metabolism; Fatty Alcohols - pharmacology; Furans - chemistry; Furans - pharmacology; Lactones - chemistry; Lactones - metabolism; Lactones - pharmacology; Mitochondria, Heart - drug effects; Mitochondria, Heart - metabolism; NADH, NADPH Oxidoreductases - antagonists & inhibitors; NADH, NADPH Oxidoreductases - metabolism; Oxidation-Reduction; Ruthenium - chemistry; Seeds - metabolism; Substrate Specificity
• ISSN: 0006-2960; 1520-4995
• DOI: 10.1021/bi051261u

Heterocyclic analogues of squamocin have been semisynthesized by condensation reactions between squamocin-derived α-keto esters and heterodinucleophiles. The strong complex I inhibitory potency of squamocin-benzimidazole, a hybrid derivative, illustrates for the first time the functional analogy existing between the terminal butenolide of annonaceous acetogenins and heteroaromatic substructures of classic inhibitors of the enzyme. This finding supports the categorization of this atypical group of inhibitors as antagonists of the ubiquinone substrates. In addition, competition experiments of squamocin-benzimidazole versus squamocin and rolliniastatin-2 suggest that the binding of this hybrid inhibitor is responsible for a negative allosteric effect at the level of the first ubiquinone-binding site (A site) of mitochondrial complex I. This result supports the existence of a large cooperatively regulated inhibitor/ubiquinone-binding pocket located within the catalytic core of the enzyme, consisting of the association of the previously defined affinity sites A and B.